Potato glycoalkaloids and adverse effects in humans: an ascending dose study

Tjeert T Mensinga1, Adrienne J A M Sips, Cathy J M Rompelberg

  • 1National Poisons Control Centre, National Institute for Public Health and the Environment, The Netherlands. tjeert.mensinga@rivm.nl

Insights

Potato glycoalkaloids, like alpha-solanine, can cause illness. This study found that glycoalkaloid clearance often exceeds 24 hours, suggesting potential accumulation with regular potato consumption.

Area of Science:

  • Food toxicology
  • Human pharmacology

Background:

  • Potato glycoalkaloids (PGs) such as alpha-solanine and alpha-chaconine can cause adverse effects.
  • These effects include gastrointestinal issues and systemic toxicity via acetylcholinesterase inhibition.

Purpose of the Study:

  • To evaluate the toxicity and pharmacokinetics of orally administered potato glycoalkaloids in humans.
  • To gather pharmacokinetic data for over 24 hours post-dose, which is novel for human studies.

Main Methods:

  • A single-dose study involving human volunteers.
  • Administration of varying doses of total glycoalkaloids (TGA) via solutions or mashed potatoes.
  • Doses ranged from 0.30 to 1.25 mg/kg body weight.

Main Results:

  • No acute systemic effects were observed across most treatments.
  • One participant experienced nausea and vomiting at the highest TGA dose (1.25 mg/kg BW).
  • Glycoalkaloid clearance typically takes longer than 24 hours.

Conclusions:

  • Potato glycoalkaloids may accumulate with daily consumption due to slow clearance rates.
  • The findings highlight potential risks associated with glycoalkaloid intake from potatoes.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...